ATE287963T1 - Pseudomonas exotoxin - myelin basisches protein chimäre proteine - Google Patents
Pseudomonas exotoxin - myelin basisches protein chimäre proteineInfo
- Publication number
- ATE287963T1 ATE287963T1 AT96937486T AT96937486T ATE287963T1 AT E287963 T1 ATE287963 T1 AT E287963T1 AT 96937486 T AT96937486 T AT 96937486T AT 96937486 T AT96937486 T AT 96937486T AT E287963 T1 ATE287963 T1 AT E287963T1
- Authority
- AT
- Austria
- Prior art keywords
- myelin basic
- basic protein
- mbp
- moiety
- amino acids
- Prior art date
Links
- 102000047918 Myelin Basic Human genes 0.000 title abstract 3
- 101710107068 Myelin basic protein Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 title 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical group C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 2
- 102000054064 human MBP Human genes 0.000 abstract 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 241000700199 Cavia porcellus Species 0.000 abstract 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
- 239000002095 exotoxin Substances 0.000 abstract 1
- 231100000776 exotoxin Toxicity 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11604495A IL116044A0 (en) | 1995-11-17 | 1995-11-17 | Chimeric proteins |
| IL11655995A IL116559A (en) | 1995-11-17 | 1995-12-26 | Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence |
| PCT/IL1996/000151 WO1997019179A1 (en) | 1995-11-17 | 1996-11-17 | Pseudomonas exotoxin - myelin basic protein chimeric proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE287963T1 true ATE287963T1 (de) | 2005-02-15 |
Family
ID=26323172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96937486T ATE287963T1 (de) | 1995-11-17 | 1996-11-17 | Pseudomonas exotoxin - myelin basisches protein chimäre proteine |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6531133B1 (de) |
| EP (1) | EP0862637B1 (de) |
| JP (1) | JP3906447B2 (de) |
| KR (1) | KR100530817B1 (de) |
| CN (1) | CN1196791C (de) |
| AT (1) | ATE287963T1 (de) |
| AU (1) | AU717617B2 (de) |
| DE (1) | DE69634263T2 (de) |
| IL (1) | IL116559A (de) |
| WO (1) | WO1997019179A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
| US6252040B1 (en) * | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| IL116436A (en) | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
| US20030054012A1 (en) * | 2000-05-12 | 2003-03-20 | Fitzgerald David J. | Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response |
| AU731703B2 (en) * | 1997-07-11 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Pseudomonas exotoxin A-like chimeric immunogens |
| US7314632B1 (en) | 1997-07-11 | 2008-01-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pseudomonas exotoxin A-like chimeric immunogens |
| US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| IL159894A0 (en) | 2001-07-17 | 2004-06-20 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| AU2003275985A1 (en) * | 2002-06-12 | 2003-12-31 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
| CN100417414C (zh) | 2003-04-30 | 2008-09-10 | 苏黎世大学 | 免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用 |
| AU2006210769A1 (en) * | 2005-02-01 | 2006-08-10 | Research Development Foundation | BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders |
| WO2011101870A1 (en) * | 2010-02-22 | 2011-08-25 | Transgene Biotek Ltd. | Fusion proteins for the treatment of multiple sclerosis and other autoimmune diseases |
| CN102167732B (zh) * | 2010-12-10 | 2013-08-21 | 厦门大学 | 蛋白类杀藻化合物及其制备方法 |
| EP2904004B1 (de) | 2012-10-04 | 2018-11-21 | Research Development Foundation | Serinproteasemoleküle und therapien |
| WO2017143026A1 (en) | 2016-02-16 | 2017-08-24 | Research Development Foundation | Sortase-modified molecules and uses thereof |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2521010B1 (fr) * | 1982-02-09 | 1985-07-19 | Sanofi Sa | Medicaments comportant en tant qu'association au moins une immunotoxine et au moins un ionophore carboxylique monovalent |
| US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
| US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
| US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
| US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| AU641392B2 (en) * | 1989-04-21 | 1993-09-23 | Protein Design Laboratories, Inc. | Recombinant antibody-toxin fusion protein |
| AU7886491A (en) * | 1990-05-14 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Improved pseudomonas chimeric protein cytotoxic to human cells bearing il2 receptors |
| US5734023A (en) * | 1991-11-19 | 1998-03-31 | Anergen Inc. | MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses |
| ES2172044T3 (es) | 1992-04-09 | 2002-09-16 | Autoimmune Inc | Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina. |
| US6045796A (en) * | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| US5681571A (en) * | 1993-10-08 | 1997-10-28 | Duotol Ab | Immunological tolerance-inducing agent |
| US5763585A (en) * | 1993-10-13 | 1998-06-09 | Anergen, Inc. | Method of making MHC-peptide complexes using metal chelate affinity chromatography |
| US5824315A (en) * | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
| US5759546A (en) * | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
| US5935577A (en) * | 1998-01-23 | 1999-08-10 | Autoimmune Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
-
1995
- 1995-12-26 IL IL11655995A patent/IL116559A/xx not_active IP Right Cessation
-
1996
- 1996-11-17 AU AU75040/96A patent/AU717617B2/en not_active Ceased
- 1996-11-17 US US09/077,028 patent/US6531133B1/en not_active Expired - Fee Related
- 1996-11-17 KR KR1019980703699A patent/KR100530817B1/ko not_active IP Right Cessation
- 1996-11-17 CN CNB961994703A patent/CN1196791C/zh not_active Expired - Fee Related
- 1996-11-17 AT AT96937486T patent/ATE287963T1/de not_active IP Right Cessation
- 1996-11-17 DE DE69634263T patent/DE69634263T2/de not_active Expired - Fee Related
- 1996-11-17 EP EP96937486A patent/EP0862637B1/de not_active Expired - Lifetime
- 1996-11-17 WO PCT/IL1996/000151 patent/WO1997019179A1/en active IP Right Grant
- 1996-11-17 JP JP51956297A patent/JP3906447B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000513562A (ja) | 2000-10-17 |
| IL116559A (en) | 2005-11-20 |
| JP3906447B2 (ja) | 2007-04-18 |
| IL116559A0 (en) | 1996-03-31 |
| EP0862637B1 (de) | 2005-01-26 |
| WO1997019179A1 (en) | 1997-05-29 |
| KR100530817B1 (ko) | 2006-01-27 |
| AU717617B2 (en) | 2000-03-30 |
| CN1196791C (zh) | 2005-04-13 |
| KR19990067671A (ko) | 1999-08-25 |
| US6531133B1 (en) | 2003-03-11 |
| EP0862637A1 (de) | 1998-09-09 |
| DE69634263D1 (en) | 2005-03-03 |
| DE69634263T2 (de) | 2005-12-22 |
| AU7504096A (en) | 1997-06-11 |
| CN1207132A (zh) | 1999-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE287963T1 (de) | Pseudomonas exotoxin - myelin basisches protein chimäre proteine | |
| GR3034140T3 (en) | CD2-Binding domain of lymphocyte function associated antigen 3. | |
| GEP20032977B (en) | Proteinase K-Resistant Surface Protein of Neisseria Meningitidis | |
| GR3030811T3 (en) | Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof | |
| DE10075019I2 (de) | Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung. | |
| DE68916932D1 (de) | Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus. | |
| Suran et al. | N-terminal sequences of heavy and light chains of leopard shark immunoglobulins: evolutionary implications. | |
| PT666914E (pt) | Nova proteina ligando da selectina p | |
| DK0494294T3 (da) | Bakterielle stressproteiner | |
| DE69018926D1 (de) | Vakzine gegen Bordetella. | |
| MX9203138A (es) | Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos. | |
| AU2750092A (en) | Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid | |
| PT789764E (pt) | Nova familia de inibidores de protease e outras substancias biologicas activas | |
| WO1996018646A3 (en) | Heat shock protein peptides and methods for modulating autoimmune central nervous system disease | |
| NO890174L (no) | Rekombinante interleukin-1alfa-polypeptider. | |
| WO1998015626A3 (en) | Mutant ciita molecule and uses thereof | |
| ATE103979T1 (de) | Menschliches lymphotoxin. | |
| MX9206732A (es) | Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas de tierra. | |
| AU692213B2 (en) | Equine arteritis virus peptides, antibodies and their use in a diagnostic test | |
| IT1276765B1 (it) | Gene del cromosoma x umano e proteina codificata da detto gene. | |
| NO923828L (no) | Polypeptider, nyttige til diagnose av og behandling mot mycoplasma-infeksjoner hos dyr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |